BioCryst's Orladeyo: Patent Landscape and Litigation in 2025
BioCryst Pharmaceuticals is involved in patent disputes concerning its hereditary angioedema (HAE) treatment, Orladeyo (berotralstat) [1]. These legal challenges primarily focus on the patents protecting the drug's composition of matter and methods of use [1].
What are the key patents for Orladeyo?
The primary patents for Orladeyo include its composition of matter patents, which broadly cover the molecule berotralstat. Additionally, method of use patents exist, detailing specific ways the drug can be administered or used to treat HAE [1]. DrugPatentWatch.com tracks these and other relevant patents for pharmaceutical products [2].
When do Orladeyo's patents expire?
The expiration dates for Orladeyo's patents vary. Some key patents are expected to expire in the coming years, with potential market exclusivity extensions or loss of exclusivity occurring around 2025 or later, depending on patent challenges and any granted extensions [1][2].
Why are companies challenging BioCryst's Orladeyo patents?
Companies seeking to introduce generic versions of Orladeyo often challenge the validity or enforceability of its patents. By invalidating or circumventing these patents, they aim to gain market entry with their own biosimilar or generic products earlier than they otherwise would [1].
What is the status of BioCryst's Orladeyo patent litigation?
BioCryst has faced and may continue to face litigation concerning its Orladeyo patents. These legal battles typically involve patent infringement lawsuits filed by BioCryst against generic manufacturers, or challenges to patent validity brought by potential competitors [1]. Specific outcomes and ongoing proceedings can be complex and are subject to court decisions.
Can biosimilars enter the market before patent expiry?
Generally, biosimilars cannot legally enter the market until the relevant patents and exclusivity periods have expired or have been successfully challenged in court. Patent litigation plays a crucial role in determining the timeline for biosimilar entry [1].
How does Orladeyo compare to other HAE treatments?
Orladeyo is an oral, once-daily, small molecule therapy for the prophylactic treatment of HAE. It targets the target enzyme of plasma kallikrein. Other HAE treatments include self-administered injections and intravenous therapies, which differ in their mechanism of action and administration routes [3].
What are the potential risks for BioCryst regarding Orladeyo's patent challenges?
The primary risk for BioCryst is the early loss of market exclusivity for Orladeyo if its patents are invalidated or circumvented. This could lead to the introduction of lower-cost generic competitors, potentially impacting Orladeyo's revenue and market share [1].
---
* Sources
[1] DrugPatentWatch.com (Information on drug patents, litigation, and expiration dates)
[2] DrugPatentWatch.com - Berotralstat (Orladeyo) Patent Information: https://drugpatentwatch.com/drug/berotralstat
[3] BioCryst Pharmaceuticals, Inc. (Information regarding Orladeyo's indication and mechanism of action)